| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N B Pai, S C Vell. Reason for clozapine cessation. Acta psychiatrica Scandinavica. vol 125. issue 1. 2012-04-16. PMID:22017729. |
the gold standard for treatment of refractory schizophrenia is clozapine. |
2012-04-16 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Gopal Vyas, Charles M Richardson, Maju Koola, Robert P McMahon, Robert W Buchanan, Heidi J Wehrin. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophrenia research. vol 133. issue 1-3. 2012-04-09. PMID:21872445. |
adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. |
2012-04-09 |
2023-08-12 |
Not clear |
| Leslie Citrome, Jan Volavk. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS drugs. vol 25. issue 12. 2012-04-04. PMID:22133324. |
for patients with schizophrenia and persistent aggressive behaviour, clozapine is recommended both for its superior antipsychotic effect and its specific anti-hostility effect. |
2012-04-04 |
2023-08-12 |
Not clear |
| Ali Ghaleiha, Navid Honarbakhsh, Mohammad-Ali Boroumand, Morteza Jafarinia, Mina Tabrizi, Farzin Rezaei, Maedeh Raznahan, Shahin Akhondzade. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human psychopharmacology. vol 26. issue 2. 2012-03-30. PMID:21412846. |
correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. |
2012-03-30 |
2023-08-12 |
Not clear |
| Ali Ghaleiha, Navid Honarbakhsh, Mohammad-Ali Boroumand, Morteza Jafarinia, Mina Tabrizi, Farzin Rezaei, Maedeh Raznahan, Shahin Akhondzade. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human psychopharmacology. vol 26. issue 2. 2012-03-30. PMID:21412846. |
the authors undertook this study to further evaluate the level of adenosine deaminase (ada) in patients with chronic schizophrenia treated with monotherapy of haloperidol, risperidone or clozapine and correlation between the ada level with response to treatment. |
2012-03-30 |
2023-08-12 |
Not clear |
| Hsiang-Hsuan Huang, Ying-Chieh Wang, Chia-Liang Wu, Chen-Jee Hong, Ya-Mei Bai, Shih-Jen Tsai, Ying-Jay Lio. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neuroscience letters. vol 504. issue 3. 2012-03-15. PMID:21967963. |
tnf-α -308 g>a polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. |
2012-03-15 |
2023-08-12 |
human |
| Hsiang-Hsuan Huang, Ying-Chieh Wang, Chia-Liang Wu, Chen-Jee Hong, Ya-Mei Bai, Shih-Jen Tsai, Ying-Jay Lio. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neuroscience letters. vol 504. issue 3. 2012-03-15. PMID:21967963. |
a total of 500 patients with schizophrenia treated with clozapine (n=275), olanzapine (n=79) or risperidone (n=146) for an average of 49.9 months were recruited. |
2012-03-15 |
2023-08-12 |
human |
| Eduardo J Aguilar, Samuel G Siri. Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacology bulletin. vol 40. issue 3. 2012-03-13. PMID:18007574. |
although clozapine has not yet demonstrated a specific preventing effect on completed suicide in patients with schizophrenia, it should be considered when suicide risk is detected in a patient with schizophrenia. |
2012-03-13 |
2023-08-12 |
Not clear |
| Chia-Chun Hung, Pin-Kuei Fu, Hsyn-Yi Wang, Chin-Hong Chan, Tsuo-Hung La. Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. vol 9. issue 5. 2012-03-12. PMID:21565135. |
it is reported that 30% to 80% schizophrenia patients suffered from hypersalivation when taking clozapine. |
2012-03-12 |
2023-08-12 |
Not clear |
| Yu-Tao Xiang, Chuan-Yue Wang, Tian-Mei Si, Edwin H M Lee, Yan-Ling He, Gabor S Ungvari, Helen F K Chiu, Naotaka Shinfuku, Shu-Yu Yang, Mian-Yoon Chong, Ee-Heok Kua, Senta Fujii, Kang Sim, Michael K H Yong, Jitendra K Trivedi, Eun-Kee Chung, Pichet Udomratn, Kok-Yoon Chee, Norman Sartorius, Lisa B Dixon, Julie A Kreyenbuhl, Chay-Hoon Ta. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. The Australian and New Zealand journal of psychiatry. vol 45. issue 11. 2012-03-06. PMID:21888603. |
clozapine use in schizophrenia: findings of the research on asia psychotropic prescription (reap) studies from 2001 to 2009. |
2012-03-06 |
2023-08-12 |
Not clear |
| Ashish Aggarwal, Dinesh Dutt Sharm. Amisulpride for clozapine induced sialorrhea. Psychopharmacology bulletin. vol 42. issue 4. 2012-02-23. PMID:20581795. |
clozapine is an atypical and novel antipsychotic medication useful for patients with schizophrenia who are refractory to treatment. |
2012-02-23 |
2023-08-12 |
Not clear |
| Selim El-Badri, Graham Mellso. Clozapine use and outcomes among patients with treatment resistant schizophrenia. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 19. issue 5. 2012-02-23. PMID:21864010. |
clozapine use and outcomes among patients with treatment resistant schizophrenia. |
2012-02-23 |
2023-08-12 |
Not clear |
| Rajiv Tando. Antipsychotics in the treatment of schizophrenia: an overview. The Journal of clinical psychiatry. vol 72 Suppl 1. 2012-02-23. PMID:22217436. |
findings concerning efficacy for positive symptoms and disorganization suggest no consistent differences among available antipsychotics, with the exception of clozapine's superior efficacy for treatment-resistant schizophrenia. |
2012-02-23 |
2023-08-12 |
Not clear |
| John Midkiff, Nathan Borochoff-Porte, Dylan White, Douglas I Johnso. Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PloS one. vol 6. issue 9. 2012-02-10. PMID:21966518. |
notably, the bht inhibitor clozapine, a fda-approved drug used to treat atypical schizophrenia by inhibiting g-protein-coupled dopamine receptors in the brain, and several of its functional analogs were shown to act at the level of the gpr1 g-protein-coupled receptor. |
2012-02-10 |
2023-08-12 |
spider |
| Joseph I Friedman, Jean-Pierre Lindenmayer, Frances Alcantara, Stephanie Bowler, Mohan Parak, Leonard White, Adel Iskander, Michael Parrella, David N Adler, Nicholas D Tsopelas, Wei-Yann Tsai, Vladan Novakovic, Vladan Novakovick, Philip D Harvey, Kenneth L Davis, Saurabh Kaushi. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 6. 2012-02-09. PMID:21346734. |
pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. |
2012-02-09 |
2023-08-12 |
Not clear |
| Joseph I Friedman, Jean-Pierre Lindenmayer, Frances Alcantara, Stephanie Bowler, Mohan Parak, Leonard White, Adel Iskander, Michael Parrella, David N Adler, Nicholas D Tsopelas, Wei-Yann Tsai, Vladan Novakovic, Vladan Novakovick, Philip D Harvey, Kenneth L Davis, Saurabh Kaushi. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 6. 2012-02-09. PMID:21346734. |
despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. |
2012-02-09 |
2023-08-12 |
Not clear |
| Joseph I Friedman, Jean-Pierre Lindenmayer, Frances Alcantara, Stephanie Bowler, Mohan Parak, Leonard White, Adel Iskander, Michael Parrella, David N Adler, Nicholas D Tsopelas, Wei-Yann Tsai, Vladan Novakovic, Vladan Novakovick, Philip D Harvey, Kenneth L Davis, Saurabh Kaushi. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 6. 2012-02-09. PMID:21346734. |
therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. |
2012-02-09 |
2023-08-12 |
Not clear |
| Tristram A P Lett, Arun K Tiwari, Herbert Y Meltzer, Jeffrey A Lieberman, Steven G Potkin, Aristotle N Voineskos, James L Kennedy, Daniel J Mülle. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia research. vol 132. issue 2-3. 2012-02-09. PMID:21890328. |
the putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. |
2012-02-09 |
2023-08-12 |
Not clear |
| Tristram A P Lett, Arun K Tiwari, Herbert Y Meltzer, Jeffrey A Lieberman, Steven G Potkin, Aristotle N Voineskos, James L Kennedy, Daniel J Mülle. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia research. vol 132. issue 2-3. 2012-02-09. PMID:21890328. |
the rs1045881 variant was not significantly associated with schizophrenia (n=302 case-control pairs), but with clozapine response (n=163; p=0.030). |
2012-02-09 |
2023-08-12 |
Not clear |
| Raouf Igue, Stéphane Potvin, Ramatoulaye Bah, Emmanuel Stip, Roch-Hugo Bouchard, Olivier Lipp, Alain Gendron, Edouard Kouass. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 7. 2012-02-08. PMID:21627977. |
quetiapine is a second-generation antipsychotic with a pharmacological profile similar to that of clozapine, but its immunomodulatory effects have not been investigated in schizophrenia yet. |
2012-02-08 |
2023-08-12 |
Not clear |